Alexander Gluzman, MD
Critical Care Medicine · Marietta, GANPI 1194900704
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,620, 3.0 times the $537 reported in 2019.
Across 213 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$920
- Insmed, Inc.$472
- GSK$457
- Pfizer$273
- Verona Pharma, Inc.$261
- Amgen$175
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,30198%
- Education$712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $920 |
| Insmed, Inc. | 21 | $472 |
| GSK | 33 | $457 |
| Pfizer | 18 | $273 |
| Verona Pharma, Inc. | 9 | $261 |
| Amgen | 9 | $175 |
| Regeneron Healthcare Solutions, Inc. | 7 | $163 |
| Boehringer Ingelheim | 7 | $154 |
| Johnson & Johnson(2 entities) | 11 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $150 |
| Harmony Biosciences LLC | 7 | $141 |
| Sanofi | 7 | $133 |
| Actelion Pharmaceuticals US, Inc. | 5 | $120 |
| Grifols USA, LLC | 5 | $117 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Jazz Pharmaceuticals Inc. | 3 | $73 |
| Merck | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Viatris Specialty LLC | 2 | $49 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| Edwards Lifesciences | 1 | $35 |
| ZOLL Medical Corporation | 1 | $33 |
| United Therapeutics Corporation | 1 | $32 |
| Mylan Specialty L.p. | 2 | $32 |
| Novartis | 1 | $28 |
| Pulmonx Corporation | 1 | $24 |
| Advanced Respiratory, Inc | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Olympus America Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Gilead | 1 | $15 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$252
How this compares
$4,372 in reported general payments places this provider in the 85th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 285 | $241,553 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $103,303 |
| EliquisApixaban | 107 | $86,948 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $81,065 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 91 | $57,350 |
| Dupixent PenDupilumab | 14 | $54,842 |
| Dupixent SyringeDupilumab | 13 | $50,703 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $50,315 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $46,027 |
| XareltoRivaroxaban | 36 | $39,235 |
| Spiriva RespimatTiotropium Bromide | 33 | $17,041 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $16,544 |
| Spiriva HandihalerTiotropium Bromide | 15 | $12,452 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $11,398 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $8,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $457 | $376,505538 claims |
| Grifols USA, LLCProlastin C | $117 | $103,30312 claims |
| PfizerEliquis | $273 | $86,948107 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $154 | $85,790147 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $920 | $66,859129 claims |
| Johnson & JohnsonXarelto | $151 | $39,23536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Marietta
- Asif SaberiMarietta$5K
- Sarah BlackstockMarietta$4K
- Craig PattersonMarietta$4K
- Nikulkumar ChaudhariMarietta$2K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.